Author:
Vela Emili,Carot-Sans Gerard,Clèries Montse,Monterde David,Acebes Xènia,Comella Adrià,García Eroles Luís,Coca Marc,Valero-Bover Damià,Pérez Sust Pol,Piera-Jiménez Jordi
Abstract
AbstractThe shortage of recently approved vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted the need for evidence-based tools to prioritize healthcare resources for people at higher risk of severe coronavirus disease (COVID-19). Although age has been identified as the most important risk factor (particularly for mortality), the contribution of underlying comorbidities is often assessed using a pre-defined list of chronic conditions. Furthermore, the count of individual risk factors has limited applicability to population-based “stratify-and-shield” strategies. We aimed to develop and validate a COVID-19 risk stratification system that allows allocating individuals of the general population into four mutually-exclusive risk categories based on multivariate models for severe COVID-19, a composite of hospital admission, transfer to intensive care unit (ICU), and mortality among the general population. The model was developed using clinical, hospital, and epidemiological data from all individuals among the entire population of Catalonia (North-East Spain; 7.5 million people) who experienced a COVID-19 event (i.e., hospitalization, ICU admission, or death due to COVID-19) between March 1 and September 15, 2020, and validated using an independent dataset of 218,329 individuals with COVID-19 confirmed by reverse transcription—polymerase chain reaction (RT-PCR), who were infected after developing the model. No exclusion criteria were defined. The final model included age, sex, a summary measure of the comorbidity burden, the socioeconomic status, and the presence of specific diagnoses potentially associated with severe COVID-19. The validation showed high discrimination capacity, with an area under the curve of the receiving operating characteristics of 0.85 (95% CI 0.85–0.85) for hospital admissions, 0.86 (0.86–0.97) for ICU transfers, and 0.96 (0.96–0.96) for deaths. Our results provide clinicians and policymakers with an evidence-based tool for prioritizing COVID-19 healthcare resources in other population groups aside from those with higher exposure to SARS-CoV-2 and frontline workers.
Funder
Servei Català de la Salut
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Bachmann, M. F., Mohsen, M. O., Zha, L., Vogel, M. & Speiser, D. E. SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. npj Vaccines. 6(1), 1–4 (2021).
2. McKeigue, P.M., Colhoun, H.M. Evaluation of “stratify and shield” as a policy option for ending the COVID-19 lockdown in the UK. medRxiv. 2020.04.25.20079913 (2020).
3. Gupta, R.K., Marks, M., Samuels, T.H.A., Luintel, A., Rampling, T., Chowdhury, H. et al. Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study. Eur. Respir. J. 56(6) (2020).
4. Henkens, M.T.H.M., Raafs, A.G., Verdonschot, J.A.J., Van Smeden, M., Wang, P., Van Der Hooft, B.H.M. et al. Age is the Main Determinant of COVID-19 Related in-Hospital Mortality with Minimal Impact of Pre-Existing Comorbidities: A Retrospective Cohort Study. (2021)
5. World Health Organization. Fair allocation mechanism for COVID-19 vaccines through the COVAX Facility [Internet]. 2020 [cited 2021 Jan 9]. 1–17. Available from: https://www.who.int/publications/m/item/fair-allocation-mechanism-for-covid-19-vaccines-through-the-covax-facility
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献